| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022079443 |
| P356 | DOI | 10.1007/S00280-016-3013-Y |
| P698 | PubMed publication ID | 27002325 |
| P50 | author | Yoshinori Mori | Q89036577 |
| Takaya Shimura | Q41434640 | ||
| P2093 | author name string | Makoto Nakamura | |
| Takashi Joh | |||
| Hiromi Kataoka | |||
| Hisato Mochizuki | |||
| Hitoshi Sano | |||
| Kyoji Seno | |||
| Takashi Kawai | |||
| Takashi Mizushima | |||
| Yoshikazu Hirata | |||
| Kenji Tsuchida | |||
| Kazunori Adachi | |||
| Yusuke Mizuno | |||
| Satoshi Sobue | |||
| Makoto Natsume | |||
| Mika Kitagawa | |||
| Atsuyuki Hirano | |||
| Hirotada Nishie | |||
| P2860 | cites work | Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation | Q51838966 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study | Q34654832 | ||
| Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers | Q36635208 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments | Q37629143 | ||
| Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). | Q37632143 | ||
| Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas | Q40022137 | ||
| Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). | Q41542192 | ||
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial | Q42285544 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| P433 | issue | 5 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 957-962 | |
| P577 | publication date | 2016-03-22 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer | |
| P478 | volume | 77 |
| Q48327644 | A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). |
| Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers |
| Q50642054 | Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients |
| Q54109361 | Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. |
| Q28072366 | Long non-coding RNAs in anti-cancer drug resistance |
| Q41992584 | Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes |
Search more.